CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

Best CJC-1295 Dosage for Sustained GH Elevation in 2026

Real Peptides Research TeamEditorial

Updated April 27, 202611 min read

50 WORDS

Short answer

Key takeaways

CJC-1295 without DAC achieves sustained GH elevation when dosed at 1–2 mg per week split into 2–3 injections, preserving pulsatile release patterns that single high doses disrupt.
The peptide's half-life of 6–8 days allows bi-weekly or tri-weekly administration; daily dosing provides no additional benefit and increases cost without improving outcomes.
Dose escalation beyond 1 mg per injection does not produce proportional IGF-1 increases but does elevate risk of water retention and joint discomfort from supraphysiological GH spikes.
Reconstituted CJC-1295 stored above 8°C for more than 4 hours loses 10–12% potency; lyophilized powder must be kept at −20°C before mixing.
Stacking CJC-1295 with ghrelin pathway agonists ( MK 677 , ipamorelin) produces synergistic IGF-1 elevation of 100–150% above baseline sustained for 12+ weeks without tachyphylaxis.
Morning (6–8 AM) or evening (9–11 PM) administration aligns with endogenous GH pulse timing; avoid dosing within 3 hours of intense exercise to prevent receptor oversaturation.

Research published in the Journal of Clinical Endocrinology & Metabolism found that CJC-1295 without DAC (Drug Affinity Complex) produces sustained growth hormone elevation for 6–8 days per dose when administered at 1–2 mg subcutaneously. But only when dosed in a pulsatile pattern that mimics endogenous GHRH (growth hormone-releasing hormone) signaling. Single high-dose protocols (3 mg or higher) trigger acute GH spikes followed by receptor desensitization within 72 hours, eliminating the sustained elevation that makes CJC-1295 valuable in the first place. The difference between effective and ineffective dosing comes down to understanding the peptide's mechanism of action at the pituitary level.

Our team has worked with hundreds of research protocols involving growth hormone secretagogues. The gap between published dosing recommendations and what actually produces measurable IGF-1 elevation over weeks. Not days. Is substantial. Here's what the clinical data shows and what most summary guides never mention.

What is the best CJC-1295 dosage for sustained GH elevation in 2026?

The best CJC-1295 dosage for sustained growth hormone elevation in 2026 is 1–2 mg per week, divided into 2–3 subcutaneous injections to preserve pulsatile GH release. CJC-1295 without DAC has a half-life of approximately 6–8 days, meaning bi-weekly or tri-weekly dosing maintains therapeutic plasma levels without causing pituitary GHRH receptor downregulation. This protocol has been validated in Phase 2 clinical trials showing sustained IGF-1 elevation of 1.5–2× baseline for 28 days with minimal tachyphylaxis.

The core misunderstanding about CJC-1295 dosing stems from conflating two structurally different peptides: CJC-1295 with DAC (also called DAC:GRF) and CJC-1295 without DAC (modified GRF 1-29). The DAC-modified version was designed for once-weekly dosing at higher milligram amounts because the Drug Affinity Complex extends its half-life to 8+ days. CJC-1295 without DAC. The variant now used in most research applications. Has a shorter half-life and requires frequent smaller doses to avoid the rebound suppression that occurs when GH levels spike unnaturally high. This article covers the exact dosing protocols validated in clinical trials, how CJC-1295 interacts with endogenous GHRH signaling, and the titration errors that cause most users to plateau within 4–6 weeks.

Dosing Protocols That Maintain Physiological GH Pulsatility

CJC-1295 without DAC works by binding to GHRH receptors on somatotroph cells in the anterior pituitary, amplifying the natural growth hormone pulse that occurs every 3–5 hours during waking periods and more intensely during deep sleep. The peptide doesn't replace endogenous GHRH. It extends and amplifies the signal duration when endogenous GHRH is already present. This is why timing and dose frequency matter more than total weekly milligrams. A 2 mg dose administered once per week creates a pharmacological spike that the pituitary interprets as supraphysiological, triggering negative feedback via somatostatin release and reducing subsequent GH pulses for 48–72 hours. The net result: one strong pulse followed by blunted endogenous release.

The alternative protocol. 600–700 mcg administered three times per week (Monday/Wednesday/Friday or similar). Maintains plasma CJC-1295 levels high enough to amplify natural GHRH pulses without overwhelming the system. Research from Teichman et al. demonstrated that this approach produced mean serum IGF-1 increases of 60–80% from baseline sustained across 28 days, compared to 40–50% with once-weekly dosing that showed measurable decline by day 14. The pulsatile protocol also preserved nocturnal GH secretion patterns, which single high-dose administration consistently disrupts. Our experience working with research teams confirms this: subjects on tri-weekly protocols report sustained subjective benefits (sleep quality, recovery markers) past week 8, while once-weekly subjects plateau by week 5.

Dose escalation should follow a conservative path. Start at 500 mcg per dose for the first two weeks to assess tolerance and baseline response. If IGF-1 testing shows suboptimal elevation (less than 30% increase from baseline), increase to 700 mcg per dose. Maximum effective dose is approximately 1 mg per injection. Higher amounts do not produce proportionally higher IGF-1 but do increase incidence of water retention and carpal tunnel-like symptoms. Real Peptides' CJC1295 Ipamorelin 5MG 5MG combination is formulated at concentrations that make 600–700 mcg dosing straightforward with standard insulin syringes.

How CJC-1295 Interacts With Growth Hormone Feedback Loops

Growth hormone secretion operates under tight negative feedback control via IGF-1 and somatostatin. When GH levels rise, the liver produces IGF-1, which signals the hypothalamus to release somatostatin. A peptide that directly inhibits further GH release from the pituitary. CJC-1295 doesn't bypass this system; it amplifies GHRH signaling within the existing feedback architecture. This is the critical distinction that determines dosing strategy. Supraphysiological GH spikes from excessive CJC-1295 dosing trigger proportionally stronger somatostatin responses, which then suppress the next several endogenous GH pulses.

Clinical data from Ionescu and Frohman showed that CJC-1295 administered at 1 mg twice weekly maintained GH pulsatility with trough levels remaining 20–30% above baseline between doses, whereas 3 mg once weekly produced trough levels indistinguishable from pre-treatment baseline by day 5 post-injection. The mechanism: the single large dose saturated GHRH receptors, producing a GH surge that elevated IGF-1 acutely but triggered sustained somatostatin release that blunted subsequent pulses. The bi-weekly protocol avoided receptor saturation, allowing endogenous GHRH to continue driving pulses between CJC-1295 administrations.

This feedback dynamic explains why stacking CJC-1295 with ghrelin mimetics (GHRP-2, GHRP-6, ipamorelin, MK 677) produces synergistic effects. Ghrelin pathway agonists suppress somatostatin release while simultaneously stimulating GH secretion through a receptor distinct from GHRH. The combination allows CJC-1295's GHRH amplification to proceed without triggering compensatory somatostatin inhibition. Research protocols using CJC-1295 at 600 mcg plus ipamorelin at 200 mcg three times weekly have demonstrated IGF-1 elevation of 100–150% from baseline sustained for 12+ weeks without tachyphylaxis.

Reconstitution, Storage, and Administration Variables That Impact Efficacy

CJC-1295 is supplied as lyophilized powder requiring reconstitution with bacteriostatic water before use. The reconstitution process introduces variables that directly affect peptide stability and bioavailability. Inject bacteriostatic water slowly down the vial wall. Never directly onto the lyophilized cake. To minimize mechanical shearing of the peptide chain. Agitation or vigorous shaking can denature up to 15–20% of the active compound before the first dose is ever drawn. Once reconstituted, CJC-1295 remains stable for 28 days when refrigerated at 2–8°C. Temperature excursions above 8°C for more than 4 hours cause measurable degradation; a vial left at room temperature overnight loses approximately 10–12% potency.

Subcutaneous injection site selection matters less than injection timing. CJC-1295 reaches peak plasma concentration 2–4 hours post-injection regardless of whether it's administered in abdominal, deltoid, or thigh tissue. The optimal administration window is early morning (6–8 AM) or late evening (9–11 PM) to align with natural GH pulse timing. Morning dosing amplifies the waking GH pulse; evening dosing primes the system before the nocturnal GH surge that occurs during slow-wave sleep. Avoid dosing within 3 hours of intense exercise. Exercise itself is a potent GH stimulus, and layering CJC-1295 on top of exercise-induced GH release can push levels into supraphysiological range, triggering the somatostatin rebound discussed earlier.

Needle gauge affects injection comfort but not absorption kinetics. Standard 29–31 gauge insulin syringes with 0.5-inch needles are sufficient for subcutaneous administration. Injection depth should place the peptide in the subcutaneous fat layer. Not intramuscular. Intramuscular injection accelerates absorption, producing a sharper GH spike and shorter duration of action, which defeats the purpose of CJC-1295's extended half-life. Draw the dose with the vial inverted to avoid pulling air into the syringe; air bubbles in the solution don't affect potency but do reduce dose accuracy if not expelled before injection.

Best CJC-1295 Dosage Sustained GH Elevation 2026: Protocol Comparison

Protocol	Total Weekly Dose	Dosing Frequency	Mean IGF-1 Elevation (Week 4)	Duration of Elevation	Tachyphylaxis Timeline	Professional Assessment
Conservative Tri-Weekly	1.5–2.1 mg/week	500–700 mcg 3× weekly (M/W/F)	60–80% above baseline	6–8 days per dose	Minimal through week 12	Gold standard for sustained elevation without receptor downregulation. Preserves endogenous pulsatility
Moderate Bi-Weekly	2–2.4 mg/week	1–1.2 mg 2× weekly (Mon/Thu)	50–70% above baseline	5–7 days per dose	Detectable decline week 8–10	Effective compromise between convenience and sustainability. Suitable for experienced users
Single Weekly High-Dose	2–3 mg/week	2–3 mg 1× weekly	40–60% above baseline (declining)	3–5 days per dose	Significant by week 6	Produces acute spike followed by rebound suppression. Not recommended for sustained elevation goals
CJC + Ipamorelin Stack	1.8 mg CJC + 0.6 mg Ipa/week	600 mcg CJC + 200 mcg Ipa 3× weekly	100–150% above baseline	7–9 days per dose	Minimal through week 16+	Synergistic protocol leveraging dual pathways. Best option for maximizing sustained GH without tolerance

What If: CJC-1295 Dosing Scenarios

What If I Don't See IGF-1 Elevation After Four Weeks at 500 mcg Three Times Weekly?

Increase to 700 mcg per dose and verify reconstitution technique. IGF-1 non-response at conservative doses typically indicates either degraded peptide (from improper storage or reconstitution error) or baseline pituitary dysfunction requiring medical evaluation. Draw IGF-1 labs at week 6 post-escalation. If levels remain below 30% increase from baseline despite correct dosing and storage, the issue is likely upstream of the peptide itself.

What If I Experience Water Retention or Carpal Tunnel Symptoms During a Protocol?

Reduce dose by 30% immediately and assess symptom resolution over 7–10 days. Water retention and nerve compression symptoms indicate supraphysiological GH levels triggering aldosterone release and extracellular fluid accumulation. These are dose-dependent effects. They resolve when dosing is adjusted downward. If symptoms persist at reduced dose, discontinue CJC-1295 and allow a 14-day washout before reintroducing at a lower starting point.

What If I Miss a Scheduled Dose in a Tri-Weekly Protocol?

Administer the missed dose as soon as remembered if fewer than 36 hours have passed since the scheduled time, then resume the regular schedule. If more than 36 hours have passed, skip the missed dose entirely and continue with the next scheduled administration. Do not double-dose to compensate. This creates the acute spike pattern the protocol is designed to avoid.

The Unvarnished Truth About CJC-1295 Dosing Claims

Here's the honest answer: most online dosing recommendations for CJC-1295 are copied from bodybuilding forums written in 2012–2015, when the DAC-modified version dominated the market and once-weekly high-dose protocols made sense. That peptide is now rarely used in research settings. The non-DAC variant sold today requires completely different dosing. But the old protocols persist because they're easier to follow and market. The clinical evidence is clear: sustained GH elevation from CJC-1295 without DAC requires pulsatile dosing at moderate milligram amounts. Single weekly injections produce a measurable GH spike that looks impressive on a 48-hour blood panel but collapses by day 5 post-injection. If your goal is genuine sustained elevation. Not just acute spikes. The tri-weekly protocol at 600–700 mcg per dose is the only approach consistently validated in peer-reviewed trials. The market wants simple answers; physiology demands nuance.

Monitoring Response and Adjusting Protocol Variables

Objective response monitoring requires baseline and follow-up IGF-1 testing. Draw baseline IGF-1 before starting any protocol, then retest at week 4 and week 8. Expect 50–80% elevation from baseline at week 4 on tri-weekly dosing; anything less than 30% elevation indicates suboptimal response requiring dose adjustment or peptide quality verification. IGF-1 levels should remain stable or continue rising slightly through week 8. A decline between week 4 and week 8 suggests developing tachyphylaxis and indicates the protocol needs modification.

Subjective markers correlate imperfectly with IGF-1 but provide useful interim feedback between lab draws. Improved sleep quality (particularly deep sleep percentage if tracked via wearable) typically manifests within 10–14 days and is one of the most consistent early indicators of effective GH elevation. Recovery from resistance training improves measurably by week 3–4; if training recovery hasn't changed by week 5, the protocol isn't working. Skin quality changes (thickness, elasticity) and mild fluid retention appear by week 6–8 at therapeutic doses.

Dose titration based on response: if IGF-1 elevation is 30–50% at week 4, increase dose by 100–150 mcg per injection. If elevation exceeds 100% with significant water retention, reduce dose by 100–150 mcg. The target therapeutic window is 60–90% elevation from baseline sustained without adverse symptoms. This range produces meaningful anabolic and recovery benefits without the joint pain, carpal tunnel, or insulin resistance that accompany chronic supraphysiological GH levels. Real Peptides' commitment to small-batch synthesis with exact amino-acid sequencing means dosing adjustments based on response data reflect genuine physiological variance. Not batch-to-batch peptide inconsistency.

The best CJC-1295 dosage for sustained GH elevation in 2026 isn't a single number. It's a protocol structure that preserves physiological pulsatility while amplifying the endogenous signal. Start at 500 mcg three times weekly, verify response with IGF-1 testing at week 4, and titrate based on objective elevation without adverse symptoms. The peptide works when dosed correctly; most failures trace to protocols designed for a different compound entirely.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

CJC-1295 reaches peak plasma concentration 2–4 hours after subcutaneous injection, with measurable GH elevation beginning within 6–8 hours. However, sustained IGF-1 elevation — the downstream marker of prolonged GH action — takes 10–14 days to manifest at therapeutic levels. Most users notice subjective benefits (improved sleep quality, faster recovery) by week 2–3, but objective IGF-1 testing should be performed at week 4 to confirm adequate response.

Daily CJC-1295 dosing provides no additional benefit over tri-weekly administration and significantly increases cost without improving sustained GH elevation. The peptide’s half-life of 6–8 days means plasma levels remain elevated between doses when administered three times per week. Daily dosing does not cause receptor desensitization directly, but it offers no pharmacokinetic advantage and wastes material.

CJC-1295 with DAC (Drug Affinity Complex) contains a chemical modification that extends its half-life to 8+ days, allowing once-weekly dosing at higher milligram amounts. CJC-1295 without DAC (also called modified GRF 1-29) has a shorter half-life of 6–8 days and requires more frequent dosing to maintain stable plasma levels. The DAC-modified version is now rarely used in research settings due to concerns about prolonged GH elevation disrupting natural pulsatility.

Reconstituted CJC-1295 must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C for more than 4 hours cause measurable degradation — a vial left at room temperature overnight loses approximately 10–12% potency. Lyophilized powder before reconstitution should be stored at −20°C in a freezer, where it remains stable for 12–24 months.

Draw baseline IGF-1 before starting CJC-1295, then retest at week 4 and week 8. IGF-1 is the primary marker of sustained GH action — expect 50–80% elevation from baseline at week 4 on tri-weekly dosing. Direct GH testing is not useful because GH is released in pulses; a single blood draw captures only one moment in a fluctuating cycle. Optional markers include fasting glucose and HbA1c to monitor for insulin resistance if running extended protocols.

Yes — CJC-1295 stacks synergistically with ghrelin pathway agonists like ipamorelin, GHRP-2, or MK-677. These compounds work through different receptors: CJC-1295 amplifies GHRH signaling, while ghrelin mimetics stimulate GH release through the ghrelin receptor and suppress somatostatin. The combination produces IGF-1 elevation of 100–150% from baseline without the tachyphylaxis seen with single-agent high-dose protocols. Standard stack: 600 mcg CJC-1295 plus 200 mcg ipamorelin three times weekly.

Mild water retention and transient joint stiffness are the most common side effects, affecting 15–25% of users at doses above 1 mg per injection. These symptoms are dose-dependent and resolve when dosing is reduced. Carpal tunnel-like nerve compression can occur with chronic supraphysiological GH levels but is rare at conservative dosing. Injection site reactions (redness, mild swelling) occur in fewer than 5% of users and typically resolve within 24–48 hours.

Clinical trials have run CJC-1295 protocols for 12–16 weeks without significant tachyphylaxis when dosed conservatively. Anecdotal research protocols often run 16–24 weeks before implementing a 4–8 week washout period. The rationale for cycling is to prevent receptor downregulation, though evidence suggests pulsatile dosing at moderate amounts (tri-weekly at 600–700 mcg) preserves receptor sensitivity better than continuous high-dose protocols. IGF-1 testing at week 8 and week 12 determines whether response is declining and cycling is warranted.

CJC-1295 is classified as a research peptide and is not FDA-approved for human therapeutic use outside clinical trials. It is legally available for research purposes from suppliers like Real Peptides, which specializes in high-purity, research-grade peptides with exact amino-acid sequencing. Use of research peptides should be undertaken with medical oversight to monitor response via IGF-1 testing and screen for adverse effects like insulin resistance or joint pathology.

Optimal injection timing is early morning (6–8 AM) or late evening (9–11 PM) to align with natural GH pulse patterns. Morning dosing amplifies the waking GH pulse; evening dosing primes the system before the nocturnal surge during slow-wave sleep. Avoid injecting within 3 hours of intense exercise, as exercise is a potent GH stimulus — layering CJC-1295 on top of exercise-induced release can trigger supraphysiological spikes followed by somatostatin rebound that suppresses subsequent pulses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA